US President Donald Trump has signed an executive order aimed at accelerating access to medical research and treatment based on psychedelic drugs. Reuters reports this, UNN informs.
Details
It is noted that the US Food and Drug Administration should, in particular, consider the use of ibogaine, which, according to veteran organizations, can help in the treatment of post-traumatic stress disorder.
At an Oval Office event, US federal officials said the reforms would pave the way for the reclassification of drugs that can cause hallucinations and are largely illegal, following successful clinical trials. Trump also said the US would allocate $50 million for federal research into ibogaine.
It is indicated that during the signing ceremony of the decree, Trump stated that he had recently learned about ibogaine.
"I've heard a little bit about it over the last year. ... I hadn't heard anything about it before. It was almost taboo. It's no longer taboo," the US president said.
Reference
Ibogaine is a substance derived from an African shrub. In the US, it is classified as a drug with a high risk of abuse. At the same time, in some countries, particularly Mexico, there are treatment centers using ibogaine.
Recall
The US Department of Health is beginning to study the impact of mobile device radiation on humans. The FDA has removed pages from its website that claimed mobile phones were completely safe.
Trump claims “progress” in stopping drug supplies from Venezuela15.11.25, 09:27